BlackRock
EGRX

BlackRock’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-268,169
Closed -$1M – 5521
2024
Q3 		$1M Sell
268,169
-84,593
-24% -$404K ﹤0.01% 4173
2024
Q2 		$1.98M Sell
352,762
-545,044
-61% -$2.37M ﹤0.01% 3968
2024
Q1 		$4.7M Sell
897,806
-87,102
-9% -$478K ﹤0.01% 3694
2023
Q4 		$5.15M Buy
984,908
+95,829
+11% +$946K ﹤0.01% 3683
2023
Q3 		$14M Sell
889,079
-121,558
-12% -$2.18M ﹤0.01% 3137
2023
Q2 		$19.6M Sell
1,010,637
-865,462
-46% -$20.5M ﹤0.01% 3049
2023
Q1 		$53.2M Buy
1,876,099
+1,651
+0.1% +$49K ﹤0.01% 2403
2022
Q4 		$54.8M Buy
1,874,448
+11,515
+0.6% +$366K ﹤0.01% 2396
2022
Q3 		$49.2M Sell
1,862,933
-74,431
-4% -$2.73M ﹤0.01% 2441
2022
Q2 		$86.1M Sell
1,937,364
-44,969
-2% -$2.07M ﹤0.01% 2120
2022
Q1 		$98.1M Buy
1,982,333
+13,517
+0.7% +$649K ﹤0.01% 2151
2021
Q4 		$100M Sell
1,968,816
-77,470
-4% -$4.01M ﹤0.01% 2220
2021
Q3 		$114M Sell
2,046,286
-35,897
-2% -$1.77M ﹤0.01% 2128
2021
Q2 		$89.1M Buy
2,082,183
+100,812
+5% +$4.16M ﹤0.01% 2325
2021
Q1 		$82.7M Buy
1,981,371
+40,355
+2% +$1.87M ﹤0.01% 2295
2020
Q4 		$90.4M Buy
1,941,016
+33,415
+2% +$1.56M ﹤0.01% 2142
2020
Q3 		$81M Buy
1,907,601
+178,282
+10% +$7.8M ﹤0.01% 2017
2020
Q2 		$83M Buy
1,729,319
+57,596
+3% +$2.87M ﹤0.01% 1957
2020
Q1 		$76.9M Sell
1,671,723
-136,789
-8% -$6.86M ﹤0.01% 1803
2019
Q4 		$109M Buy
1,808,512
+82,655
+5% +$4.93M ﹤0.01% 1912
2019
Q3 		$97.6M Sell
1,725,857
-17,837
-1% -$1M ﹤0.01% 1911
2019
Q2 		$97.1M Buy
1,743,694
+83,722
+5% +$4.37M ﹤0.01% 1934
2019
Q1 		$83.8M Sell
1,659,972
-71,082
-4% -$3.16M ﹤0.01% 1981
2018
Q4 		$69.7M Sell
1,731,054
-10,658
-0.6% -$549K ﹤0.01% 2033
2018
Q3 		$121M Buy
1,741,712
+309,622
+22% +$23.5M 0.01% 1849
2018
Q2 		$108M Buy
1,432,090
+183,287
+15% +$11.5M 0.01% 1886
2018
Q1 		$65.8M Buy
1,248,803
+16,405
+1% +$954K ﹤0.01% 2106
2017
Q4 		$65.8M Sell
1,232,398
-29,187
-2% -$1.62M ﹤0.01% 2115
2017
Q3 		$75.2M Buy
1,261,585
+62,706
+5% +$3.79M ﹤0.01% 2030
2017
Q2 		$94.6M Sell
1,198,879
-7,974
-0.7% -$652K 0.01% 1835
2017
Q1 		$100M Buy
1,206,853
+1,206,197
+183,871% +$89.7M 0.01% 1774
2016
Q4 		$52K Sell
656
-120
-15% -$8.72K ﹤0.01% 2911
2016
Q3 		$54K Buy
776
+55
+8% +$3.05K ﹤0.01% 2925
2016
Q2 		$28K Buy
721
+218
+43% +$9.08K ﹤0.01% 3166
2016
Q1 		$21K Buy
503
+312
+163% +$19.8K ﹤0.01% 2830
2015
Q4 		$17K Hold
191
– – ﹤0.01% 2667
2015
Q3 		$14K Sell
191
-2,073
-92% -$172K ﹤0.01% 2583
2015
Q2 		$183K Buy
+2,264
New +$147K ﹤0.01% 1695

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

BlackRock's EGRX Position: Q4 2024 in Review

BlackRock sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 268,169 shares — an estimated $1M sold.

BlackRock first reported a position in EGRX in Q2 2015 and held it in 38 quarters. The position peaked at $121M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • BlackRock reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • BlackRock sold 268,169 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $1M.
  • BlackRock first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 38 quarters.
  • BlackRock's Eagle Pharmaceuticals, Inc. position peaked at $121M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.